UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 0-12697
(Exact name of registrant as specified in its charter)
|
87-0398434
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
7030 Park Centre Drive, Cottonwood Heights, UT 84121
(Address of principal executive offices, Zip Code)
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☑ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
|
Non-accelerated filer ☐ (Do not check if a smaller reporting company)
|
Smaller reporting company ☑
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No
The number of shares outstanding of the registrant's common stock, no par value, as of November 9, 2015 is 2,672,652.
QUARTER ENDED SEPTEMBER 30, 2015
|
Page Number
|
|
|
PART I. FINANCIAL INFORMATION
|
|
|
|
Item 1. Financial Statements
|
1
|
|
|
Condensed Consolidated Balance Sheets (Unaudited)
|
|
As of September 30, 2015 and June 30, 2015
|
1
|
|
|
Condensed Consolidated Statements of Operations (Unaudited)
|
|
Three Months Ended September 30, 2015 and 2014
|
2
|
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited)
|
|
Three Months Ended September 30, 2015 and 2014
|
3
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
4
|
|
|
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
|
9
|
|
|
Item 3. Quantitative and Qualitative Disclosures About Market Risk
|
14
|
|
|
Item 4. Controls and Procedures
|
14
|
|
|
PART II. OTHER INFORMATION
|
|
|
|
|
15
|
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Dynatronics Corporation ("Company," "Dynatronics," "we") designs, manufactures, distributes, markets and sells physical medicine products. We offer a broad line of medical equipment including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. We market and sell our products primarily to physical therapists, chiropractors, sports medicine practitioners and podiatrists. We operate on a fiscal year ending June 30. For example, reference to fiscal year 2016 refers to the year ending June 30, 2016.
Recent Events
In July 2015, we received the
Conformité Européen Mark (CE Mark), granting approval for our SolarisPlus and "25 Series" therapeutic modality products. The CE Mark is an indication that these products meet the requirements of applicable European Community directives for manufacturing. This approval allows us to sell these products in Europe and many other countries around the world. Distributors have been established in Great Britain and Portugal. We also received clearance in Japan to sell our proprietary Solaris Plus line of products in the last year. With distributors signed in Mexico, as well as China and other countries of Southeast Asia, we are actively seeking clearance for our Solaris Plus product line in those countries. As a result of these recent approvals and agreements, we expect international sales growth to accelerate as we extend our geographical reach and become a provider of these products on a more global scale.
In June 2015, we completed a $4.0 million private placement led by affiliates of Prettybrook Partners, a strategic private equity investor focused on the healthcare industry. The financing provides us with additional capital to promote organic growth and pursue potential strategic acquisitions. With the notable experience of Dr. Stuart Essig and Erin Enright from Prettybrook, we believe we have added partners that can help us make transformative improvements that will benefit the Company and its shareholders. Our goal is to transform Dynatronics into a platform for accelerated growth, both organically and through tactical and carefully-planned acquisitions in order to capitalize on important healthcare trends. In the private placement, we issued accredited investors 1.6 million shares of Series A preferred stock (convertible share-for-share into common stock of the Company) and warrants to purchase 2.4 million shares of common stock.
Business Outlook
The strategic direction of the past few months, including the completion of the sale of preferred stock to affiliates of Prettybrook Partners, are designed to accelerate our growth in the coming years. The financing has significantly strengthened our balance sheet and provides the resources to increase our market and geographic footprint while maintaining our status as the innovative leader in rehabilitation and physical therapy products.
Combining the solid corporate infrastructure we have built over the last three decades with the business acumen and access to capital and deal flow provided by Prettybrook should allow Dynatronics not only to strengthen our legacy business, but also position the Company for growth through strategic acquisitions.
Our M&A strategy is focused on acquiring businesses that simultaneously fit our criteria and enhance our product offering. We are currently evaluating acquisition opportunities and anticipate executing on one of these in calendar year 2016. We believe these actions will cause Dynatronics to grow faster than our market segment.
We are also focused on growing organically, both in the US and internationally. In the last three years we have released more new and innovative products than during any other similar period in our history. The introduction of the Solaris Plus family of combination electrotherapy/ultrasound/ phototherapy units, the 25 Series combination electrotherapy/ultrasound units, the line of Ultra treatment tables, and the ThermoStim probe (an accessory to the Solaris Plus family of products) make up most of these innovative new products.
The introduction of these products has been a major strategic component of attracting new sales representatives and dealers in order to expand our distribution across North America and into international territories. Adding these new sales reps and dealers along with expanding into new markets such as podiatry, home health, hospitals and long-term care is part of our strategic plan for expanding our geographical reach and becoming a provider of therapeutic products globally.
As mentioned in the "recent events" section of this report, in July 2015, we received the CE Mark approval. The CE Mark approval of our SolarisPlus and "25 Series" therapeutic modality products allows us to sell these products in Europe and many other countries around the world. Over the past several years, we have increased our emphasis on international sales. In addition, during the past year, we also received clearance for these same products in Japan. Efforts are currently underway to obtain clearance in Mexico, China and other Southeast Asian countries. With the CE Mark, we can further expand sales throughout Europe and into areas of the world that recognize and require this distinguished mark of quality.
Our efforts in past years to prudently reduce costs in the face of some economic uncertainty have made us a leaner operation. We will continue to be vigilant in maintaining appropriate overhead costs and operating costs while still providing support for sales from our new products and supporting new initiatives for growth.
Based on our defined strategic initiatives, we are focusing our resources in the following areas:
|
Exploring strategic business acquisitions using the capital infusion from the sale of preferred stock. We believe that this will leverage and complement our competitive strengths, increase market reach and allow us to potentially expand into broader medical markets.
|
·
|
Improving gross profit margins by, among other initiatives, increasing market share of manufactured capital products by promoting sales of our state-of-the-art Dynatron ThermoStim probe, SolarisPlus and 25 Series products.
|
|
Seeking to improve distribution of our products through recruitment of additional qualified sales representatives and dealers attracted by the many new products being offered and expanding the availability of proprietary combination therapy devices.
|
|
Increasing international sales by 1) leveraging the CE Mark approval in Europe and other countries through appropriate distributors for the approved products, 2) finalizing regulatory approvals in Mexico, Peru, as well as China and other countries in Southeast Asia, and 3) further developing relationships with existing distributors in countries such as Japan in order to increase sales in those countries where products are approved.
|
|
Continuing to seek ways of increasing business with regional and national accounts and the U.S. Government.
|
|
Strengthening pricing management and procurement methodologies.
|
·
|
Updating and improving our selling and marketing efforts including electronic commerce options, as well as developing better tools for our sales force to improve their efficiency.
|
Results of Operations
The following discussion and analysis of our financial condition and results of operations for the three months ended September 30, 2015, should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto appearing in Part I, Item 1 of this report, and our Annual Report on Form 10-K for the fiscal year ended June 30, 2015, as amended, which includes audited financial statements for the year then ended. Results of operations for the first fiscal quarter ended September 30, 2015, are not necessarily indicative of the results that may be achieved for the full fiscal year ending June 30, 2016.
Three Months Ended September 30, 2015
Compared to Three Months Ended September 30, 2014
Net sales increased $0.2 million or approximately 2.5% to approximately $7.4 million for the quarter ended September 30, 2015, compared to net sales of approximately $7.2 million for the quarter ended September 30, 2014.
Higher sales
of distributed capital exercise products and metal and wood treatment tables accounted for the majority of the increase in total sales for the quarter ended September 30, 2015. The upward trend in sales reflects improving overall market conditions and increased customer confidence in our markets.
For the
quarter ended September 30, 2015
, gross
profit decreased $56,743 or about 2.2% to approximately $2.5 million, or 33.9% of net sales
. By comparison, gross profit
for the quarter ended September 30,
2014 was
approximately $2.6 million, or 35.6% of net sales
.
A significant factor in the decrease in gross profit was product mix. Sales during the quarter ended September 30, 2015 included higher sales of certain manufactured and distributed products for which our margins are lower. In addition to the shift in sales mix, our network of dealers accounted for a higher percentage of sales during the quarter. We sell to dealers at a wholesale price which has the effect of lowering gross profit margins.
Despite increasing sales by 2.5%, the lower gross profit margin on the incremental sales was insufficient to match the gross profit generated on lower sales during the same period last year. Management has developed plans for increasing gross profits by focusing sales on the Company's proprietary therapeutic devices which are primarily sold by our sales representatives and which carry higher gross margins in general. These plans are focused on improving penetration into our primary markets as well as exploring distribution into medical markets we have not previously addressed. Increasing sales of capital equipment products will be one of the keys to improving gross profit margins going forward.
Selling, General and Administrative Expenses
Selling, general and administrative ("SG&A") expenses increased approximately $0.1 million to approximately $2.4 million, or 31.8% of net sales
, for the quarter ended September 30, 2015, from approximately $2.3 million, or 31.2% of net sales, for the quarter ended September 30, 2014.
The following factors impacted SG&A expenses for the three months ended September 30, 2015:
|
$76,746 of higher labor and overhead expenses;
|
|
$32,282 of higher general expenses; and
|
·
|
$5,002 of lower selling expenses primarily associated with lower commission expense.
|
The majority of the increase in expenses is related to implementation of our strategic plans to transform the Company into a platform for growth, both organically and through carefully-planned acquisitions.
Research and Development Expenses
Research and development, or R&D expenses for the quarter ended September 30, 2015 were approximately $0.3 million or 3.6% of sales compared to approximately $0.2 million or 3.0% of sales in the quarter ended September 30, 2014. Over the past three years, we have introduced more new products than any previous three-year period in our history. The new product introductions include the innovative SolarisPlus line of electrotherapy/ultrasound/phototherapy units, the Ultra 2 and Ultra 3 motorized treatment tables, the 25 Series line of electrotherapy and ultrasound products, as well as the Dynatron ThermoStim Probe. We believe that developing new products is a key element in our strategy and critical to moving purchasing momentum in a positive direction. Increased R&D expenses in the current quarter are related to development of new products and product enhancements scheduled for release later this fiscal year. R&D costs are expensed as incurred and are expected to remain at current levels in the current fiscal year.
Income (Loss) Before Income Tax
Pre-tax loss for the quarter ended September 30, 2015, was approximately $187,212, compared to pre-tax income of $56,486 for the quarter ended September 30, 2014.
The increase in pre-tax loss for the quarter
was primarily attributable to $56,743 of lower gross profit generated during the period and approximately $0.1 million in increased expenses related to implementation of strategic plans for organic growth and acquisitions, together with $31.950 of higher interest expense and $48,534 in increased R&D expense.
Income Tax Provision (Benefit)
Income tax benefit was $5,650 for the quarter ended September 30, 2015, compared to income tax provision of $15,563 for the quarter ended September 30, 2014. In accordance with accounting rules, we recorded a full valuation allowance of approximately $62,600 on our net deferred tax assets for the quarter ended September 30, 2015. Thus, the effective tax benefit rate for the quarter ended September 30, 2015 was 3.0%, compared to an effective tax rate of 27.6% for the same quarter of the prior year. See "Liquidity and Capital Resources – Deferred Income Tax Assets" below for more information regarding the valuation allowance and its anticipated impact on the effective tax rate for 2016.
Net Income (Loss)
Net loss was approximately $181,562 for the quarter ended September 30, 2015, compared to net income of $40,923 for the quarter ended September 30, 2014.
The increase in net loss for the quarter was primarily attributable to lower gross profit generated during the period and increased expenses related to implementation of strategic plans to grow organically and through acquisitions. Other factors included higher net interest expense and increased R&D expense. It should also be noted that the valuation allowance mentioned above eliminated any tax benefit that would otherwise have been recorded during the quarter. That tax benefit would have had the effect of reducing the net loss reported.
Net Loss Applicable to Common Shareholders
Net loss Applicable to Common Shareholders was approximately $0.3 million ($.10 per share) for the quarter ended September 30, 2015, compared to net income of $40,923 ($.02 per share) for the quarter ended September 30, 2014. The Net loss Applicable to Common Shareholders includes the impact of the accrued payment of $80,500 of dividends to preferred shareholders for the quarter ended September 30, 2015. The dividend was paid in the subsequent quarter by issuing shares of our common stock having a market value of $80,500.
Liquidity and Capital Resources
We have
historically
financed operations through cash from operations, available cash reserves, and borrowings under a line of credit facility. Working capital was $7.6 million as of September 30, 2015, inclusive of the current portion of long-term obligations and credit facilities, compared to working capital of $7.7 million as of June 30, 2015. As of September 30, 2015, we had approximately $1.7 million of available credit under
our
credit facility
. The current ratio was 3.0 to 1 as of September 30, 2015 and 2.4 to 1 as of June 30, 2015.
Cash and Cash Equivalents
Our cash and cash equivalents position as of September 30, 2015, was $2.1 million, compared to cash and cash equivalents of $3.9 million as of June 30, 2015.
Approximately $0.6 million of cash was used during the quarter ended September 30, 2015 to reduce accounts payable, including approximately $0.2 million in costs related to the offer and sale of our preferred stock. Approximately $1.2 million was used to reduce debt on the Company's line of credit.
Accounts Receivable
Trade accounts receivable, net of allowance for doubtful accounts, decreased approximately $0.2 million, or 5.2%, to $3.2 million as of September 30, 2015, compared to $3.3 million as of June 30, 2015. Trade accounts receivable represent amounts due from our customers including medical practitioners, clinics, hospitals, colleges and universities and sports teams as well as dealers and distributors that purchase our products for redistribution. We believe that our estimate of the allowance for doubtful accounts is adequate based on our historical knowledge and relationship with these customers. Accounts receivable are generally collected within 30 days of the agreed terms.
Inventories, net of reserves, increased $43,880, or 0.8%, to $5.5 million as of September 30, 2015, compared to $5.4 million as of June 30, 2015. Inventory levels fluctuate based on the timing of large inventory purchases from overseas suppliers. We believe that our estimate of the allowance for inventory reserves is adequate based on our historical knowledge and product sales trends.
Accounts payable decreased approximately $0.6 million, or 22.4%, to $2.0 million as of September 30, 2015, from approximately $2.5 million as of June 30, 2015. Accounts payable are generally not aged beyond the terms of our suppliers. We take advantage of available early payment discounts when offered by our vendors.
The outstanding balance on our line of credit decreased $1.2 million to $717,819 as of September 30, 2015, compared to $1.9 million as of June 30, 2015. This reduction was made possible by the capital infusion from the sale of preferred stock on June 30, 2015 to affiliates of Prettybrook Partners. Interest on the line of credit is based on the prime rate plus 5%. The $3 million line of credit is collateralized by accounts receivable and inventories. Borrowing limitations are based on 85% of eligible accounts receivable and $0.7 million of eligible inventory. The current borrowing base on the new line of credit is approximately $2.4 million. Minimum interest payments of $5,000 are due monthly. All borrowings under the line of credit are presented as current liabilities in the accompanying consolidated balance sheet.
The line of credit matures on March 5, 2016. The Company may choose to pay off the line of credit when it matures using cash reserves. The effective interest rate on borrowed money is approximately 10% including interest and origination fees. We believe that cash balances, amounts available under the line of credit as well as cash generated from operating activities will continue to be sufficient to meet our annual operating requirements.
Debt
Long-term debt, excluding current installments decreased $31,604 to about $0.6 million as of September 30, 2015, compared to approximately $0.7 million as of June 30, 2015. Our long-term debt is comprised primarily of the mortgage loan on our office and manufacturing facility in Tennessee. The principal balance on the mortgage loan is approximately $718,000, of which approximately $0.6 million is classified as long-term debt, with monthly principal and interest payments of $13,278. Our mortgage loan matures in 2021.
In conjunction with the sale and leaseback of our corporate headquarters in August 2014, we entered into a $3.8 million capital lease for a 15-year term with an investor group. Amortization associated with that lease is recorded on a straight line basis over 15 years. Lease payments of approximately $27,000 are payable monthly. Total amortization expense related to the leased building is approximately $25,300 (net of amortized gain on sale) for the quarter ended September 30, 2015. The deferred gain on sale is being amortized over the 15-year life of the lease. Total imputed interest related to the leased building is approximately $50,700 for the quarter ended September 30, 2015.
Deferred Income Tax Assets
A valuation allowance is required when there is significant uncertainty as to the realizability of deferred tax assets. The ability to realize deferred tax assets is dependent upon our ability to generate sufficient taxable income within the carryforward periods provided for in the tax law for eachtax jurisdiction.
We have determined that we do not meet the "more likely than not" threshold that deferred tax assets will be realized. Accordingly, a valuation allowance is required. Any reversal of the valuation allowance in future periods will favorably impact the Company's results of operations in the period of reversal.
At September 30, 2015 and June 30, 2015, we recorded a full valuation allowance against our deferred tax assets and no valuation allowance at June 30, 2014.
Included in the deferred tax assets and valuation allowance is an estimated federal and state net operating loss ("NOL") of approximately $0.2 million for the quarter ended September 30, 2015.
The Company's federal and state income tax returns for June 30, 2012, 2013 and 2014 are open tax years.
Inflation
Our revenues and net income have not been unusually affected by inflation or price increases for raw materials and parts from vendors.
In February 2011, the Board of Directors approved $1.0 million for open market share repurchases of the Company's common stock. Approximately $0.5 million remained of this authorization as of September 30, 2015. No purchases were made under this plan during the three months ended September 30, 2015. The last purchase under this plan was made on September 28, 2011.
Critical Accounting Policies
The preparation of our financial statements requires that we make estimates and judgments. We base these on historical experience and on other assumptions that we believe to be reasonable. Our critical accounting policies are discussed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our Annual Report on Form 10-K for the year ended
June 30, 2015, as amended. There have been no material changes to the critical accounting policies previously disclosed in that report.
Cautionary Statement Concerning Forward-Looking Statements
The statements contained in this Form 10-Q, particularly the foregoing discussion in Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations, that are not purely historical, are "forward-looking statements" within the safe harbors provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 ("Exchange Act"). These statements refer to our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of words or phrases such as "believes," "expects," "anticipates," "should," "plans," "estimates," "intends," and "potential," among others. Forward-looking statements include, but are not limited to, statements regarding product development, market acceptance, financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements, except as required by law.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to information from that presented for the year ended June 30, 2015.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods that are specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-
15(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2015.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2015 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
|
Exhibits
|
|
|
|
Articles of Incorporation of Dynatronics Laser Corporation, incorporated by reference to Registration Statement on Form S-1 (no. 2-85045) filed and effective November 2, 1984 November 2, 1984
|
|
|
|
Articles of Amendment to Articles of Incorporation dated November 18, 1993, incorporated by reference to Annual Report on Form 10-KSB, filed September 28, 1995
|
|
|
|
Articles of Amendment to Articles of Incorporation, incorporated by reference to Current Report on Form 8-K, filed December 18, 2012
|
|
|
3.4
|
Articles of Amendment to Articles of Incorporation, incorporated by reference to Current Report on Form 8-K, filed July 1, 2015
|
|
|
3.5
|
Amended and Restated Bylaws, adopted July 20, 2015, incorporated by reference to Current Report on Form 8-K, filed July 22, 2015
|
|
|
4.1
|
Form of certificate representing common stock, no par value, incorporated by reference to a Registration Statement on Form S-1 (No. 2-85045) filed with the Securities and Exchange Commission and effective November 2, 1984
|
|
|
4.2
|
Form of certificate representing Series A 8% Convertible Preferred Stock, incorporated by reference to Ex 4.2 to Form S-3 filed July 29, 2015
|
|
|
4.3
|
Form of certificate of designations for Series A 8% Convertible Preferred Stock, incorporated by reference to Current Report on Form 8-K filed on July 1, 2015
|
|
|
4.4
|
Form of A Warrant, incorporated by reference to Current Report on Form 8-K filed on July 1, 2015
|
|
|
4.5
|
Form of B Warrant, incorporated by reference to Current Report on Form 8-K filed on July 1, 2015
|
|
|
|
Securities Purchase Agreement, dated as of May 1, 2015, filed as Appendix C to the Registrant's Preliminary Proxy Statement as filed with the Commission on May 4, 2015 and incorporated herein by reference.
|
|
|
|
Form of Registration Rights Agreement, filed as Appendix F to the Registrant's Preliminary Proxy Statement as filed with the Commission on May 4, 2015 and incorporated herein by reference.
|
|
|
|
Dynatronics Corporation 2005 Equity Incentive Award Plan (previously filed as Annex A to the Company's Definitive Proxy Statement on Schedule 14A filed on October 27, 2006)
|
|
|
|
Form of Option Agreement for the 2005 Equity Incentive Plan for incentive stock options (previously filed as Exhibit 10.8 to the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2006)
|
|
|
|
Form of Option Agreement for the 2005 Equity Incentive Plan for non-qualified options (previously filed as Exhibit 10.9 to the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2006)
|
|
|
|
Dynatronics Corporation 2015 Equity Incentive Award Plan and Forms of Statutory and Non-statutory Stock Option Awards (previously filed as exhibit to Registration Statement on Form S-8, effective September 3, 2015
|
|
|
10.7
|
Executive Employment Agreement (Cullimore) dated May 1, 2015 (filed herewith)
|
|
|
|
Executive Employment Agreement (Beardall) dated May 1, 2015 (filed herewith)
|
|
|
|
Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)
|
|
|
|
Certification under Rule 13a-14(a)/15d-14(a) of principal executive officer (filed herewith)
|
|
|
|
Certification under Rule 13a-14(a)/15d-14(a) of principal financial officer (filed herewith)
|
|
|
|
Certifications under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) (filed herewith)
|
|
|
101 INS
|
XBRL Instance Document*
|
|
|
101 SCH
|
XBRL Schema Document*
|
|
|
101 CAL
|
XBRL Calculation Linkbase Document*
|
|
|
101 DEF
|
XBRL Definition Linkbase Document*
|
|
|
101 LAB
|
XBRL Labels Linkbase Document*
|
|
|
101 PRE
|
XBRL Presentation Linkbase Document*
|
* The XBRL related information in Exhibit 101 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
DYNATRONICS CORPORATION
|
|
Registrant
|
|
|
|
|
|
/s/ Kelvyn H. Cullimore, Jr.
|
|
Kelvyn H. Cullimore, Jr.
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ Terry M. Atkinson, CPA
|
|
Terry M. Atkinson, CPA
|
|
Chief Financial Officer
|
|
(Principal Financial and Accounting Officer) |